Identification

Name
Phenelzine
Accession Number
DB00780  (APRD00099)
Type
Small Molecule
Groups
Approved
Description

An irreversible non-selective inhibitor of monoamine oxidase. May be used to treat major depressive disorder.

Structure
Thumb
Synonyms
  • Fenelzina
  • Phenelzin
  • Phénelzine
  • Phenelzinum
External IDs
W 1544
Product Ingredients
IngredientUNIICASInChI Key
Phenelzine sulfate2681D7P965156-51-4RXBKMJIPNDOHFR-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NardilTablet, film coated15 mg/1OralParke Davis Div Of Pfizer Inc1961-06-09Not applicableUs
NardilTablet15 mgOralErfa Canada 2012 Inc1981-12-31Not applicableCanada
Phenelzine SulfateTablet, film coated15 mg/1OralGreenstone, Llc1961-06-09Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Phenelzine SulfateTablet15 mg/1OralNovel Laboratories, Inc.2011-02-14Not applicableUs
Phenelzine SulfateTablet15 mg/1OralLupin Pharmaceuticals2010-12-14Not applicableUs
Phenelzine SulfateTablet15 mg/1OralGolden State Medical Supply2010-12-14Not applicableUs
International/Other Brands
Margyl (DIM) / Nardelzine (Pfizer)
Categories
UNII
O408N561GF
CAS number
51-71-8
Weight
Average: 136.1943
Monoisotopic: 136.100048394
Chemical Formula
C8H12N2
InChI Key
RMUCZJUITONUFY-UHFFFAOYSA-N
InChI
InChI=1S/C8H12N2/c9-10-7-6-8-4-2-1-3-5-8/h1-5,10H,6-7,9H2
IUPAC Name
(2-phenylethyl)hydrazine
SMILES
NNCCC1=CC=CC=C1

Pharmacology

Indication

For the treatment of major depressive disorder. Has also been used with some success in the management of bulimia nervosa.

Structured Indications
Pharmacodynamics

Phenelzine belongs to a class of antidepressants called monoamine oxidase inhibitors (MAOIs). MAO is an enzyme that catalyzes the oxidative deamination of a number of amines, including serotonin, norepinephrine, epinephrine, and dopamine. Two isoforms of MAO, A and B, are found in the body. MAO-A is mainly found within cells located in the periphery and catalyzes the breakdown of serotonin, norepinephrine, epinephrine, dopamine and tyramine. MAO-B acts on phenylethylamine, norepinephrine, epinephrine, dopamine and tyramine, is localized extracellularly and is found predominantly in the brain. While the mechanism of MAOIs is still unclear, it is thought that they act by increasing free serotonin and norepinephrine concentrations and/or by altering the concentrations of other amines in the CNS. It has been postulated that depression is caused by low levels of serotonin and/or norepinephrine and that increasing serotonergic and norepinephrinergic neurotransmission results in relief of depressive symptoms. MAO A inhibition is thought to be more relevant to antidepressant activity than MAO B inhibition. Selective MAO B inhibitors, such as selegiline, have no antidepressant effects. Response to therapy generally occurs 2 - 4 weeks following onset though some patients may not experience symptom relief for up to 8 weeks.

Mechanism of action

Although the exact mechanism of action has not been determined, it appears that the irreversible, nonselective inhibition of MAO by phenelzine relieves depressive symptoms by causing an increase in the levels of serotonin, norepinephrine, and dopamine in the neuron.

TargetActionsOrganism
AAmine oxidase [flavin-containing] A
antagonist
Human
AAmine oxidase [flavin-containing] B
antagonist
Human
UMembrane primary amine oxidase
inhibitor
Human
U4-aminobutyrate aminotransferase, mitochondrial
inhibitor
Human
UAlanine aminotransferase 1
inhibitor
Human
UAlanine aminotransferase 2
inhibitor
Human
UGlutamic acid decarboxylase
inhibitor
Human
Absorption

Readily absorbed after oral administration.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic. Acetylation of phenelzine appears to be a minor metabolic pathway. Beta-phenylethylamine is a metabolite of phenelzine, and there is indirect evidence that phenelzine may also be ring-hydroxylated and N-methylated.

Route of elimination

NARDIL ® is extensively metabolized, primarily by oxidation via monoamine oxidase.

Half life

1.2-11.6 hours following single dose administration. Multiple-dose pharmacokinetics have not been studied.

Clearance
Not Available
Toxicity

Symptoms of overdose include drowsiness, dizziness, faintness, irritability, hyperactivity, agitation, severe headache, hallucinations, trismus, opisthotonos, convulsions and coma, rapid and irregular pulse, hypertension, hypotension and vascular collapse, precordial pain, respiratory depression and failure, hyperpyrexia, diaphoresis, and cool, clammy skin. Hypertensive crisis may occur with the ingestion of tyramine-rich foods such as cured meats, poultry or fish, aged cheeses, concentrated soy products, tap beer and wine, yeast extracts, broad bean pods and fava beans and sauerkraut.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetaminePhenelzine may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetaminePhenelzine may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetaminePhenelzine may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolinePhenelzine may increase the hypertensive activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AcarbosePhenelzine may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololPhenelzine may increase the hypotensive activities of Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Aceprometazine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Acetophenazine.Approved
AlaproclateThe risk or severity of adverse effects can be increased when Alaproclate is combined with Phenelzine.Experimental
AlbiglutidePhenelzine may increase the hypoglycemic activities of Albiglutide.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Phenelzine is combined with Aldesleukin.Approved
AlfentanilAlfentanil may increase the serotonergic activities of Phenelzine.Approved, Illicit
AliskirenPhenelzine may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Phenelzine is combined with Almotriptan.Approved, Investigational
AlogliptinPhenelzine may increase the hypoglycemic activities of Alogliptin.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Phenelzine.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Phenelzine.Illicit
AlprenololPhenelzine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Phenelzine.Approved
AmbrisentanPhenelzine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Phenelzine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Phenelzine is combined with Amiloride.Approved
AmineptinePhenelzine may increase the serotonergic activities of Amineptine.Illicit, Withdrawn
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Phenelzine.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Phenelzine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Phenelzine.Approved
AmlodipinePhenelzine may increase the hypotensive activities of Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Phenelzine.Approved, Illicit
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Phenelzine.Approved, Investigational
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Phenelzine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Phenelzine is combined with Amperozide.Experimental
AmphetaminePhenelzine may increase the hypertensive activities of Amphetamine.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Phenelzine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Phenelzine is combined with Amyl Nitrite.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Phenelzine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Apraclonidine.Approved
ArbutamineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Phenelzine.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Phenelzine.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Phenelzine.Approved, Investigational
AsenapineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Asenapine.Approved
AtenololPhenelzine may increase the hypotensive activities of Atenolol.Approved
AtomoxetinePhenelzine may increase the central neurotoxic activities of Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Phenelzine is combined with Atorvastatin.Approved
AtropinePhenelzine may increase the hypertensive activities of Atropine.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Azaperone.Investigational, Vet Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Phenelzine is combined with Azilsartan medoxomil.Approved
BambuterolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Bambuterol.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Phenelzine.Experimental
BarbitalBarbital may increase the hypotensive activities of Phenelzine.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Phenelzine.Approved
BenazeprilPhenelzine may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazidePhenelzine may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinPhenelzine may increase the hypertensive activities of Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Benperidol.Investigational
BenzphetaminePhenelzine may increase the hypertensive activities of Benzphetamine.Approved, Illicit
BepridilPhenelzine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Phenelzine.Approved
BetaxololPhenelzine may increase the hypotensive activities of Betaxolol.Approved
BethanidinePhenelzine may increase the hypotensive activities of Bethanidine.Approved
BezafibrateThe risk or severity of adverse effects can be increased when Phenelzine is combined with Bezafibrate.Approved
BietaserpinePhenelzine may increase the hypotensive activities of Bietaserpine.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when Phenelzine is combined with Bifeprunox.Investigational
BimatoprostPhenelzine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololPhenelzine may increase the hypotensive activities of Bisoprolol.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Phenelzine.Approved, Investigational
BosentanPhenelzine may increase the hypotensive activities of Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Phenelzine.Approved
BQ-123Phenelzine may increase the hypotensive activities of BQ-123.Investigational
BretyliumPhenelzine may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Phenelzine is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Brimonidine.Approved
BrofarominePhenelzine may increase the hypertensive activities of Brofaromine.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Bromperidol.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Phenelzine is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Phenelzine.Approved, Investigational
BupranololPhenelzine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Phenelzine.Approved, Illicit, Investigational, Vet Approved
BupropionPhenelzine may increase the hypertensive activities of Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Phenelzine.Approved, Investigational
ButaperazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Butaperazine.Experimental
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Phenelzine.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Phenelzine.Approved
CadralazinePhenelzine may increase the hypotensive activities of Cadralazine.Experimental
CafedrinePhenelzine may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinPhenelzine may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanPhenelzine may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilPhenelzine may increase the hypotensive activities of Candesartan cilexetil.Approved
CandoxatrilPhenelzine may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilPhenelzine may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Phenelzine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Phenelzine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Phenelzine.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Cariprazine.Approved
CaroxazonePhenelzine may increase the hypertensive activities of Caroxazone.Withdrawn
CarteololPhenelzine may increase the hypotensive activities of Carteolol.Approved
CarvedilolPhenelzine may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololPhenelzine may increase the hypotensive activities of Celiprolol.Approved, Investigational
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Phenelzine.Withdrawn
ChlorothiazidePhenelzine may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphenterminePhenelzine may increase the hypertensive activities of Chlorphentermine.Illicit, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Chlorproethazine.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamidePhenelzine may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidonePhenelzine may increase the hypotensive activities of Chlorthalidone.Approved
CicletaninePhenelzine may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilPhenelzine may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Phenelzine.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Phenelzine.Approved
CirazolinePhenelzine may increase the hypertensive activities of Cirazoline.Experimental
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Phenelzine.Approved
ClemastinePhenelzine may increase the anticholinergic activities of Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Phenelzine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Clomipramine.Approved, Vet Approved
ClonidinePhenelzine may increase the hypotensive activities of Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Clopenthixol.Experimental
CloranololPhenelzine may increase the hypotensive activities of Cloranolol.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Clozapine.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Phenelzine.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Phenelzine.Approved, Investigational
CryptenaminePhenelzine may increase the hypotensive activities of Cryptenamine.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Cyamemazine.Approved
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Phenelzine.Approved
CyclopenthiazidePhenelzine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazidePhenelzine may increase the hypotensive activities of Cyclothiazide.Approved
CyproheptadinePhenelzine may increase the anticholinergic activities of Cyproheptadine.Approved
DapagliflozinPhenelzine may increase the hypoglycemic activities of Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Phenelzine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Phenelzine.Investigational
DebrisoquinPhenelzine may increase the hypotensive activities of Debrisoquin.Approved, Investigational
DelaprilPhenelzine may increase the hypotensive activities of Delapril.Experimental
DeserpidinePhenelzine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Phenelzine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Desipramine.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Desvenlafaxine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Dexmedetomidine.Approved, Vet Approved
DexmethylphenidatePhenelzine may increase the hypertensive activities of Dexmethylphenidate.Approved
DextroamphetaminePhenelzine may increase the hypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanPhenelzine may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Phenelzine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Phenelzine.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Phenelzine.Approved, Investigational
DiazoxidePhenelzine may increase the hypotensive activities of Diazoxide.Approved
DibenzepinPhenelzine may increase the serotonergic activities of Dibenzepin.Experimental
DiclofenamideThe risk or severity of adverse effects can be increased when Phenelzine is combined with Diclofenamide.Approved
diethylnorsperminePhenelzine may increase the hypotensive activities of diethylnorspermine.Investigational
DiethylpropionPhenelzine may increase the hypertensive activities of Diethylpropion.Approved, Illicit
DihydralazinePhenelzine may increase the hypotensive activities of Dihydralazine.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Phenelzine.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Phenelzine.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Phenelzine.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Phenelzine.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Phenelzine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Phenelzine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Phenelzine.Experimental, Illicit
DiltiazemPhenelzine may increase the hypotensive activities of Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Phenelzine is combined with Dinutuximab.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Phenelzine.Approved, Illicit
DipivefrinThe risk or severity of adverse effects can be increased when Phenelzine is combined with Dipivefrin.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Phenelzine is combined with Dipyridamole.Approved
DisopyramidePhenelzine may increase the hypoglycemic activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Dixyrazine.Experimental
DobutamineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Dobutamine.Approved
DolasetronDolasetron may increase the serotonergic activities of Phenelzine.Approved
DomperidoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Domperidone.Approved, Investigational, Vet Approved
DorzolamidePhenelzine may increase the hypotensive activities of Dorzolamide.Approved
DosulepinPhenelzine may increase the serotonergic activities of Dosulepin.Approved
DoxapramPhenelzine may increase the hypertensive activities of Doxapram.Approved, Vet Approved
DoxazosinPhenelzine may increase the hypotensive activities of Doxazosin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Phenelzine is combined with Doxepin.Approved
DoxylaminePhenelzine may increase the anticholinergic activities of Doxylamine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Phenelzine.Experimental
DroperidolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Droperidol.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Phenelzine.Experimental, Illicit
DroxidopaThe risk or severity of adverse effects can be increased when Phenelzine is combined with Droxidopa.Approved, Investigational
DulaglutidePhenelzine may increase the hypoglycemic activities of Dulaglutide.Approved
DuloxetinePhenelzine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Phenelzine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Phenelzine is combined with Ecopipam.Investigational
EfonidipinePhenelzine may increase the hypotensive activities of Efonidipine.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Phenelzine.Approved, Investigational
EmpagliflozinPhenelzine may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilPhenelzine may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatPhenelzine may increase the hypotensive activities of Enalaprilat.Approved
EndralazinePhenelzine may increase the hypotensive activities of Endralazine.Experimental
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Phenelzine.Approved, Investigational
EpanololPhenelzine may increase the hypotensive activities of Epanolol.Experimental
EphedraThe risk or severity of adverse effects can be increased when Phenelzine is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpinephrinePhenelzine may increase the hypertensive activities of Epinephrine.Approved, Vet Approved
EplerenoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Eplerenone.Approved
EpoprostenolPhenelzine may increase the hypotensive activities of Epoprostenol.Approved
EprosartanPhenelzine may increase the hypotensive activities of Eprosartan.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Phenelzine is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Phenelzine.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Phenelzine is combined with Escitalopram.Approved, Investigational
EsmirtazapinePhenelzine may increase the serotonergic activities of Esmirtazapine.Investigational
EsmololThe risk or severity of adverse effects can be increased when Phenelzine is combined with Esmolol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Phenelzine is combined with Etacrynic acid.Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Phenelzine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Phenelzine.Approved, Illicit
EtoperidonePhenelzine may increase the serotonergic activities of Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Phenelzine.Illicit, Vet Approved
ExenatidePhenelzine may increase the hypoglycemic activities of Exenatide.Approved, Investigational
FelodipinePhenelzine may increase the hypotensive activities of Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Fenfluramine.Illicit, Investigational, Withdrawn
FenoldopamPhenelzine may increase the hypotensive activities of Fenoldopam.Approved
FenoterolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Fenoterol.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Phenelzine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
Ferulic acidPhenelzine may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Phenelzine.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Fluanisone.Experimental
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Phenelzine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Fluphenazine.Approved
FluspirileneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Fluspirilene.Approved, Investigational
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Phenelzine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Phenelzine.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Formoterol.Approved, Investigational
FosinoprilPhenelzine may increase the hypotensive activities of Fosinopril.Approved
FrovatriptanThe risk or severity of adverse effects can be increased when Phenelzine is combined with Frovatriptan.Approved, Investigational
FurazolidonePhenelzine may increase the hypertensive activities of Furazolidone.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Phenelzine is combined with Furosemide.Approved, Vet Approved
GepefrineThe risk or severity of adverse effects can be increased when Gepefrine is combined with Phenelzine.Experimental
GliclazidePhenelzine may increase the hypoglycemic activities of Gliclazide.Approved
GlimepiridePhenelzine may increase the hypoglycemic activities of Glimepiride.Approved
GlipizidePhenelzine may increase the hypoglycemic activities of Glipizide.Approved
GlyburidePhenelzine may increase the hypoglycemic activities of Glyburide.Approved
GranisetronGranisetron may increase the serotonergic activities of Phenelzine.Approved, Investigational
GuanabenzPhenelzine may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelPhenelzine may increase the hypotensive activities of Guanadrel.Approved
GuanazodinePhenelzine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidinePhenelzine may increase the hypotensive activities of Guanethidine.Approved
GuanfacinePhenelzine may increase the hypotensive activities of Guanfacine.Approved, Investigational
GuanoclorPhenelzine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzPhenelzine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanPhenelzine may increase the hypotensive activities of Guanoxan.Experimental
HaloperidolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Phenelzine.Approved, Vet Approved
HarmalinePhenelzine may increase the hypertensive activities of Harmaline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Phenelzine.Approved, Illicit, Investigational
HexamethoniumPhenelzine may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Phenelzine.Approved
HydracarbazinePhenelzine may increase the hypertensive activities of Hydracarbazine.Experimental
HydralazinePhenelzine may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazidePhenelzine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Hydrocodone.Approved, Illicit
HydroflumethiazidePhenelzine may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Hydromorphone.Approved, Illicit
HydroxyamphetaminePhenelzine may increase the hypertensive activities of Hydroxyamphetamine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Phenelzine.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Phenelzine.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Phenelzine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Indacaterol.Approved
IndalpinePhenelzine may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamidePhenelzine may increase the hypotensive activities of Indapamide.Approved
IndenololPhenelzine may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminPhenelzine may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartPhenelzine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirPhenelzine may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlarginePhenelzine may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisinePhenelzine may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanPhenelzine may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproPhenelzine may increase the hypoglycemic activities of Insulin Lispro.Approved
Iofetamine I-123The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Phenelzine.Approved
IprindolePhenelzine may increase the serotonergic activities of Iprindole.Experimental
IproclozidePhenelzine may increase the hypertensive activities of Iproclozide.Withdrawn
IproniazidPhenelzine may increase the hypertensive activities of Iproniazid.Withdrawn
IrbesartanPhenelzine may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Phenelzine is combined with Isocarboxazid.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Phenelzine.Approved, Vet Approved
IsomethepteneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Isometheptene.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Phenelzine is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Phenelzine is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Isoxsuprine.Approved, Withdrawn
IsradipinePhenelzine may increase the hypotensive activities of Isradipine.Approved
KetanserinPhenelzine may increase the hypotensive activities of Ketanserin.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Phenelzine.Approved, Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Phenelzine.Approved, Nutraceutical, Withdrawn
LabetalolPhenelzine may increase the hypotensive activities of Labetalol.Approved
LacidipinePhenelzine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LatanoprostPhenelzine may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipinePhenelzine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Phenelzine is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Phenelzine.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Phenelzine.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Phenelzine.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Phenelzine is combined with Levomilnacipran.Approved
LevonordefrinPhenelzine may increase the hypertensive activities of Levonordefrin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Phenelzine.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Levosalbutamol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Phenelzine.Approved, Investigational
LinezolidThe risk or severity of adverse effects can be increased when Phenelzine is combined with Linezolid.Approved, Investigational
LinsidominePhenelzine may increase the hypotensive activities of Linsidomine.Experimental
LiraglutidePhenelzine may increase the hypoglycemic activities of Liraglutide.Approved
LisdexamfetaminePhenelzine may increase the hypertensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilPhenelzine may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Phenelzine.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Phenelzine is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Phenelzine.Illicit
LofepraminePhenelzine may increase the serotonergic activities of Lofepramine.Experimental
LofexidinePhenelzine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LorcaserinThe risk or severity of adverse effects can be increased when Phenelzine is combined with Lorcaserin.Approved
LosartanPhenelzine may increase the hypotensive activities of Losartan.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Phenelzine.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Loxapine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Lurasidone.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Phenelzine.Illicit, Investigational, Withdrawn
MacitentanPhenelzine may increase the hypotensive activities of Macitentan.Approved
ManidipinePhenelzine may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Phenelzine.Approved
MebanazinePhenelzine may increase the hypertensive activities of Mebanazine.Withdrawn
MecamylaminePhenelzine may increase the hypotensive activities of Mecamylamine.Approved
MecaserminPhenelzine may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MelperoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Melperone.Approved, Investigational
MephedronePhenelzine may increase the hypertensive activities of Mephedrone.Investigational
MephenterminePhenelzine may increase the hypertensive activities of Mephentermine.Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Phenelzine.Experimental
MequitazinePhenelzine may increase the anticholinergic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Mesoridazine.Approved, Investigational
MetaraminolPhenelzine may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Phenelzine.Experimental
MetforminPhenelzine may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Phenelzine.Approved, Illicit
MethamphetaminePhenelzine may increase the hypertensive activities of Methamphetamine.Approved, Illicit
MethazolamideThe risk or severity of adverse effects can be increased when Phenelzine is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Phenelzine.Approved
MethoserpidinePhenelzine may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Methotrimeprazine.Approved
MethoxaminePhenelzine may increase the hypertensive activities of Methoxamine.Approved, Investigational
MethoxyphenamineThe risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Phenelzine.Experimental
MethyclothiazideThe risk or severity of adverse effects can be increased when Phenelzine is combined with Methyclothiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Phenelzine is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Phenelzine.Experimental
Methylene bluePhenelzine may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Phenelzine.Approved
MethylphenidatePhenelzine may increase the hypertensive activities of Methylphenidate.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Phenelzine.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Phenelzine.Approved
MetipranololPhenelzine may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Phenelzine is combined with Metoclopramide.Approved, Investigational
MetolazonePhenelzine may increase the hypotensive activities of Metolazone.Approved
MetoprololPhenelzine may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosinePhenelzine may increase the hypotensive activities of Metyrosine.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Phenelzine.Experimental
MianserinPhenelzine may increase the neurotoxic activities of Mianserin.Approved, Investigational
MibefradilPhenelzine may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidodrinePhenelzine may increase the hypertensive activities of Midodrine.Approved
MidomafetaminePhenelzine may increase the hypertensive activities of Midomafetamine.Experimental, Illicit, Investigational
MifepristonePhenelzine may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolPhenelzine may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Phenelzine is combined with Milnacipran.Approved
MinaprinePhenelzine may increase the hypertensive activities of Minaprine.Approved
MinoxidilPhenelzine may increase the hypotensive activities of Minoxidil.Approved
MirtazapinePhenelzine may increase the central neurotoxic activities of Mirtazapine.Approved
MMDAPhenelzine may increase the hypertensive activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Phenelzine is combined with Moclobemide.Approved
MoexiprilPhenelzine may increase the hypotensive activities of Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Moperone.Experimental
MorphineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Morphine.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Mosapramine.Experimental
MoxonidinePhenelzine may increase the hypotensive activities of Moxonidine.Approved, Investigational
MuzoliminePhenelzine may increase the hypotensive activities of Muzolimine.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Phenelzine.Approved, Investigational
NadololPhenelzine may increase the hypotensive activities of Nadolol.Approved
NaftopidilPhenelzine may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Phenelzine.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Phenelzine is combined with Naratriptan.Approved, Investigational
NateglinidePhenelzine may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololPhenelzine may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Nefazodone.Approved, Withdrawn
NesiritideThe risk or severity of adverse effects can be increased when Phenelzine is combined with Nesiritide.Approved, Investigational
NialamidePhenelzine may increase the hypertensive activities of Nialamide.Withdrawn
NicardipinePhenelzine may increase the hypotensive activities of Nicardipine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Phenelzine.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Phenelzine.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Nifedipine.Approved
NiguldipinePhenelzine may increase the hypotensive activities of Niguldipine.Experimental
NilvadipinePhenelzine may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipinePhenelzine may increase the hypotensive activities of Nimodipine.Approved
NisoldipinePhenelzine may increase the hypotensive activities of Nisoldipine.Approved
NitrendipinePhenelzine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Phenelzine.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Phenelzine is combined with Nitroglycerin.Approved, Investigational
NitroprussidePhenelzine may increase the hypotensive activities of Nitroprusside.Approved
NorepinephrinePhenelzine may increase the hypertensive activities of Norepinephrine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Phenelzine.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Phenelzine.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Phenelzine.Approved
OctamoxinPhenelzine may increase the hypertensive activities of Octamoxin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Olanzapine.Approved, Investigational
OlmesartanPhenelzine may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Olodaterol.Approved
OmapatrilatPhenelzine may increase the hypotensive activities of Omapatrilat.Investigational
OndansetronOndansetron may increase the serotonergic activities of Phenelzine.Approved
OpipramolPhenelzine may increase the serotonergic activities of Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Phenelzine.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Orciprenaline.Approved
OsanetantThe risk or severity of adverse effects can be increased when Phenelzine is combined with Osanetant.Investigational
OxprenololPhenelzine may increase the hypotensive activities of Oxprenolol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Phenelzine.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Oxypertine.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Phenelzine.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Phenelzine.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Papaverine.Approved
PargylinePhenelzine may increase the hypotensive activities of Pargyline.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Phenelzine.Approved, Investigational
PenbutololPhenelzine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Penfluridol.Experimental
PentamidinePhenelzine may increase the hypoglycemic activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Phenelzine.Approved, Vet Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Phenelzine.Approved, Vet Approved
PentoliniumPhenelzine may increase the hypotensive activities of Pentolinium.Approved
PerazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Perazine.Investigational
PergolideThe metabolism of Pergolide can be decreased when combined with Phenelzine.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilPhenelzine may increase the hypotensive activities of Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Phenelzine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Perphenazine.Approved
PethidinePhenelzine may increase the serotonergic activities of Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Phenelzine.Experimental
PheniprazinePhenelzine may increase the hypertensive activities of Pheniprazine.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Phenelzine.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Phenelzine.Experimental
PhenoxybenzaminePhenelzine may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenelzine may increase the hypertensive activities of Phenoxypropazine.Withdrawn
PhenterminePhenelzine may increase the hypertensive activities of Phentermine.Approved, Illicit
PhentolaminePhenelzine may increase the hypotensive activities of Phentolamine.Approved
PhenylephrinePhenelzine may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PholcodinePholcodine may increase the serotonergic activities of Phenelzine.Approved, Illicit
PiclozotanThe metabolism of Piclozotan can be decreased when combined with Phenelzine.Investigational
PimozideThe risk or severity of adverse effects can be increased when Phenelzine is combined with Pimozide.Approved
PinacidilPhenelzine may increase the hypotensive activities of Pinacidil.Withdrawn
PindololPhenelzine may increase the hypotensive activities of Pindolol.Approved
PioglitazonePhenelzine may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Pipotiazine.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Phenelzine.Investigational
PirlindolePhenelzine may increase the hypertensive activities of Pirlindole.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Phenelzine.Approved
PivhydrazinePhenelzine may increase the hypertensive activities of Pivhydrazine.Withdrawn
PizotifenPhenelzine may increase the anticholinergic activities of Pizotifen.Approved
Platelet Activating FactorPhenelzine may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazidePhenelzine may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Phenelzine is combined with Pramipexole.Approved, Investigational
PramlintidePhenelzine may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Phenelzine.Approved
PrazosinPhenelzine may increase the hypotensive activities of Prazosin.Approved
PrimidonePrimidone may increase the hypotensive activities of Phenelzine.Approved, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Procarbazine.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Procaterol.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Prochlorperazine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Promethazine.Approved
PropericiazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Propericiazine.Approved
PropofolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Propofol.Approved, Investigational, Vet Approved
PropranololPhenelzine may increase the hypotensive activities of Propranolol.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Phenelzine is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Phenelzine.Approved
PRX-00023The metabolism of PRX-00023 can be decreased when combined with Phenelzine.Investigational
PseudoephedrinePhenelzine may increase the hypertensive activities of Pseudoephedrine.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Quetiapine.Approved
QuinaprilPhenelzine may increase the hypotensive activities of Quinapril.Approved, Investigational
QuininePhenelzine may increase the hypoglycemic activities of Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Phenelzine is combined with Raclopride.Investigational
RamiprilPhenelzine may increase the hypotensive activities of Ramipril.Approved
RasagilineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Phenelzine is combined with Remifentanil.Approved
RemikirenPhenelzine may increase the hypotensive activities of Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Phenelzine is combined with Remoxipride.Approved, Withdrawn
RepaglinidePhenelzine may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnaminePhenelzine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Reserpine.Approved, Investigational
RilmenidinePhenelzine may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatPhenelzine may increase the hypotensive activities of Riociguat.Approved
RisperidonePhenelzine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Phenelzine is combined with Ritanserin.Investigational
RitobegronPhenelzine may increase the hypertensive activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Ritodrine.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Phenelzine is combined with Rizatriptan.Approved
RopiniroleThe risk or severity of adverse effects can be increased when Phenelzine is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Ropivacaine.Approved
RosiglitazonePhenelzine may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Phenelzine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Phenelzine is combined with Sacubitril.Approved
SafrazinePhenelzine may increase the hypertensive activities of Safrazine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Salmeterol.Approved
SaprisartanPhenelzine may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinPhenelzine may increase the hypoglycemic activities of Saxagliptin.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Phenelzine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagPhenelzine may increase the hypotensive activities of Selexipag.Approved
SertindoleThe risk or severity of adverse effects can be increased when Phenelzine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Sevoflurane.Approved, Vet Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Phenelzine.Approved
SitagliptinPhenelzine may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SitaxentanPhenelzine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Phenelzine is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Sotalol.Approved
SpiraprilPhenelzine may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Spironolactone.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Phenelzine is combined with Streptokinase.Approved, Investigational
SuccinylcholinePhenelzine may increase the neuromuscular blocking activities of Succinylcholine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Phenelzine is combined with Sufentanil.Approved, Investigational
SulfadiazinePhenelzine may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazolePhenelzine may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazolePhenelzine may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Phenelzine is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Phenelzine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Phenelzine.Approved, Investigational
SunitinibPhenelzine may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TalinololPhenelzine may increase the hypotensive activities of Talinolol.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Phenelzine is combined with Tamsulosin.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Phenelzine.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Phenelzine.Approved
TelmisartanPhenelzine may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilPhenelzine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Phenelzine is combined with Terazosin.Approved
TerbutalineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Terbutaline.Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Phenelzine.Experimental
TerlipressinPhenelzine may increase the hypotensive activities of Terlipressin.Approved, Investigational
Testosterone PropionateThe risk or severity of adverse effects can be increased when Testosterone Propionate is combined with Phenelzine.Approved, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Phenelzine.Approved
TetrahydropalmatinePhenelzine may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TetryzolinePhenelzine may increase the hypertensive activities of Tetryzoline.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Phenelzine is combined with Thalidomide.Approved, Investigational, Withdrawn
TheodrenalinePhenelzine may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThiamylal may increase the hypotensive activities of Phenelzine.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Phenelzine.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Phenelzine is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Thioproperazine.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Thiothixene.Approved
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Phenelzine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Phenelzine is combined with Tiapride.Approved, Investigational
TibolonePhenelzine may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenPhenelzine may increase the hypotensive activities of Ticrynafen.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Phenelzine.Experimental
TimololPhenelzine may increase the hypotensive activities of Timolol.Approved
TizanidineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Tizanidine.Approved
TolazamidePhenelzine may increase the hypoglycemic activities of Tolazamide.Approved
TolazolinePhenelzine may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamidePhenelzine may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Phenelzine.Approved, Withdrawn
TolonidinePhenelzine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatonePhenelzine may increase the hypertensive activities of Toloxatone.Approved
TorasemidePhenelzine may increase the hypotensive activities of Torasemide.Approved
TramadolTramadol may increase the neuroexcitatory activities of Phenelzine.Approved, Investigational
TrandolaprilPhenelzine may increase the hypotensive activities of Trandolapril.Approved
Trans-2-PhenylcyclopropylaminePhenelzine may increase the hypertensive activities of Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Phenelzine.Approved
TravoprostPhenelzine may increase the hypotensive activities of Travoprost.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Phenelzine.Approved, Investigational
TreprostinilPhenelzine may increase the hypotensive activities of Treprostinil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Phenelzine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Triamterene.Approved
TrichlormethiazidePhenelzine may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Trifluoperazine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Triflupromazine.Approved, Vet Approved
TrimazosinPhenelzine may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanPhenelzine may increase the hypotensive activities of Trimethaphan.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Phenelzine.Approved
TropisetronTropisetron may increase the serotonergic activities of Phenelzine.Approved, Investigational
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Phenelzine.Approved, Investigational, Nutraceutical
UnoprostonePhenelzine may increase the hypotensive activities of Unoprostone.Approved
UrapidilPhenelzine may increase the hypotensive activities of Urapidil.Investigational
ValsartanPhenelzine may increase the hypotensive activities of Valsartan.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Phenelzine.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Phenelzine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Phenelzine is combined with Veralipride.Experimental
VerapamilThe risk or severity of adverse effects can be increased when Phenelzine is combined with Verapamil.Approved
VilanterolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Vilanterol.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Phenelzine.Approved
VincaminePhenelzine may increase the hypotensive activities of Vincamine.Experimental
VinpocetinePhenelzine may increase the hypotensive activities of Vinpocetine.Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Phenelzine.Approved
XipamidePhenelzine may increase the hypotensive activities of Xipamide.Experimental
XylometazolinePhenelzine may increase the hypotensive activities of Xylometazoline.Approved
ZimelidinePhenelzine may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Ziprasidone.Approved
ZofenoprilPhenelzine may increase the hypotensive activities of Zofenopril.Experimental
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Phenelzine.Approved, Investigational
ZotepineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid aged foods (cheese, red wine), pickled foods, cured foods (bacon/ham), chocolate, fava beans, beer, unless approved by your physician.
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Avoid St.John's Wort.
  • Take without regard to meals.

References

General References
  1. Nolen WA: [Classical monoamine oxidase inhibitor: not registered for, but still a place in the treatment of depression]. Ned Tijdschr Geneeskd. 2003 Oct 4;147(40):1940-3. [PubMed:14574774]
  2. Sowa BN, Holt A, Todd KG, Baker GB: Monoamine oxidase inhibitors, their structural analogues, and neuroprotection. Indian J Exp Biol. 2004 Sep;42(9):851-7. [PubMed:15462176]
External Links
Human Metabolome Database
HMDB14918
KEGG Drug
D08349
KEGG Compound
C07430
PubChem Compound
3675
PubChem Substance
46507348
ChemSpider
3547
BindingDB
50105417
ChEBI
8060
ChEMBL
CHEMBL1089
Therapeutic Targets Database
DAP000578
PharmGKB
PA450903
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Phenelzine
ATC Codes
N06AF03 — Phenelzine
AHFS Codes
  • 28:16.04.12 — Monoamine Oxidase Inhibitors
FDA label
Download (38.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingTreatmentAdenocarcinoma, Prostate / Hormone-Resistant Prostate Cancer / Metastatic Prostatic Adenocarcinoma / Recurrent Prostate Carcinoma1
2RecruitingTreatmentAdenocarcinoma of the Prostate / Recurrent Prostate Cancer / Stage I Prostate Cancer / Stage IIA Prostate Cancer / Stage IIB Prostate Cancer / Stage III Prostate Cancer1

Pharmacoeconomics

Manufacturers
  • Parke davis div warner lambert co
Packagers
Dosage forms
FormRouteStrength
TabletOral15 mg
TabletOral15 mg/1
Tablet, film coatedOral15 mg/1
Prices
Unit descriptionCostUnit
Phenelzine sulfate powder51.0USD g
Nardil 15 mg tablet0.95USD tablet
Nardil 15 mg Tablet0.39USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)< 25 °CPhysProp
boiling point (°C)74 °C at 1.00E-01 mm HgPhysProp
water solubility29.1 g/LNot Available
logP1.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility11.1 mg/mLALOGPS
logP1.2ALOGPS
logP1.2ChemAxon
logS-1.1ALOGPS
pKa (Strongest Basic)5.55ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area38.05 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity54.26 m3·mol-1ChemAxon
Polarizability15.8 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9926
Blood Brain Barrier+0.9405
Caco-2 permeable+0.6863
P-glycoprotein substrateNon-substrate0.6728
P-glycoprotein inhibitor INon-inhibitor0.9439
P-glycoprotein inhibitor IINon-inhibitor0.9767
Renal organic cation transporterNon-inhibitor0.6026
CYP450 2C9 substrateNon-substrate0.9166
CYP450 2D6 substrateNon-substrate0.5788
CYP450 3A4 substrateNon-substrate0.8056
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorInhibitor0.8945
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorInhibitor0.8995
CYP450 3A4 inhibitorInhibitor0.7961
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7748
Ames testAMES toxic0.6836
CarcinogenicityCarcinogens 0.699
BiodegradationNot ready biodegradable0.8301
Rat acute toxicity2.6507 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7405
hERG inhibition (predictor II)Non-inhibitor0.8735
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0a4l-9800000000-fec970db2245559d8531
Mass Spectrum (Electron Ionization)MSsplash10-0002-9000000000-833e467e14c48ae4f6b3
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0900000000-cf09dbe619ab21f16ce0

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Not Available
Direct Parent
Benzene and substituted derivatives
Alternative Parents
Alkylhydrazines / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Monocyclic benzene moiety / Alkylhydrazine / Organic nitrogen compound / Organopnictogen compound / Hydrocarbon derivative / Organonitrogen compound / Hydrazine derivative / Aromatic homomonocyclic compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
primary amine (CHEBI:8060) / a small molecule (CPD-13895)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Serotonin binding
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOA
Uniprot ID
P21397
Uniprot Name
Amine oxidase [flavin-containing] A
Molecular Weight
59681.27 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Chiche F, Le Guillou M, Chetrite G, Lasnier F, Dugail I, Carpene C, Moldes M, Feve B: Antidepressant phenelzine alters differentiation of cultured human and mouse preadipocytes. Mol Pharmacol. 2009 May;75(5):1052-61. doi: 10.1124/mol.108.052563. Epub 2009 Feb 6. [PubMed:19201819]
  3. Chenu F, El Mansari M, Blier P: Long-term administration of monoamine oxidase inhibitors alters the firing rate and pattern of dopamine neurons in the ventral tegmental area. Int J Neuropsychopharmacol. 2009 May;12(4):475-85. doi: 10.1017/S1461145708009218. Epub 2008 Aug 13. [PubMed:18700056]
  4. Wooters TE, Bardo MT: The monoamine oxidase inhibitor phenelzine enhances the discriminative stimulus effect of nicotine in rats. Behav Pharmacol. 2007 Nov;18(7):601-8. [PubMed:17912044]
  5. Volz HP, Gleiter CH: Monoamine oxidase inhibitors. A perspective on their use in the elderly. Drugs Aging. 1998 Nov;13(5):341-55. [PubMed:9829163]
  6. Nolen WA: [Classical monoamine oxidase inhibitor: not registered for, but still a place in the treatment of depression]. Ned Tijdschr Geneeskd. 2003 Oct 4;147(40):1940-3. [PubMed:14574774]
  7. Pickar D, Murphy DL, Cohen RM, Campbell IC, Lipper S: Selective and nonselective monoamine oxidase inhibitors: behavioral disturbances during their administration to depressed patients. Arch Gen Psychiatry. 1982 May;39(5):535-40. [PubMed:7092487]
  8. MacKenzie EM, Grant SL, Baker GB, Wood PL: Phenelzine causes an increase in brain ornithine that is prevented by prior monoamine oxidase inhibition. Neurochem Res. 2008 Mar;33(3):430-6. Epub 2007 Aug 31. [PubMed:17768678]
  9. McIntyre RS, Soczynska JK, Konarski JZ, Kennedy SH: The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf. 2006 Jan;5(1):157-68. [PubMed:16370964]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Primary amine oxidase activity
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOB
Uniprot ID
P27338
Uniprot Name
Amine oxidase [flavin-containing] B
Molecular Weight
58762.475 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Chiche F, Le Guillou M, Chetrite G, Lasnier F, Dugail I, Carpene C, Moldes M, Feve B: Antidepressant phenelzine alters differentiation of cultured human and mouse preadipocytes. Mol Pharmacol. 2009 May;75(5):1052-61. doi: 10.1124/mol.108.052563. Epub 2009 Feb 6. [PubMed:19201819]
  3. Chenu F, El Mansari M, Blier P: Long-term administration of monoamine oxidase inhibitors alters the firing rate and pattern of dopamine neurons in the ventral tegmental area. Int J Neuropsychopharmacol. 2009 May;12(4):475-85. doi: 10.1017/S1461145708009218. Epub 2008 Aug 13. [PubMed:18700056]
  4. Wooters TE, Bardo MT: The monoamine oxidase inhibitor phenelzine enhances the discriminative stimulus effect of nicotine in rats. Behav Pharmacol. 2007 Nov;18(7):601-8. [PubMed:17912044]
  5. Volz HP, Gleiter CH: Monoamine oxidase inhibitors. A perspective on their use in the elderly. Drugs Aging. 1998 Nov;13(5):341-55. [PubMed:9829163]
  6. Nolen WA: [Classical monoamine oxidase inhibitor: not registered for, but still a place in the treatment of depression]. Ned Tijdschr Geneeskd. 2003 Oct 4;147(40):1940-3. [PubMed:14574774]
  7. Pickar D, Murphy DL, Cohen RM, Campbell IC, Lipper S: Selective and nonselective monoamine oxidase inhibitors: behavioral disturbances during their administration to depressed patients. Arch Gen Psychiatry. 1982 May;39(5):535-40. [PubMed:7092487]
  8. McIntyre RS, Soczynska JK, Konarski JZ, Kennedy SH: The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf. 2006 Jan;5(1):157-68. [PubMed:16370964]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Tryptamine:oxygen oxidoreductase (deaminating) activity
Specific Function
Cell adhesion protein that participates in lymphocyte extravasation and recirculation by mediating the binding of lymphocytes to peripheral lymph node vascular endothelial cells in an L-selectin-in...
Gene Name
AOC3
Uniprot ID
Q16853
Uniprot Name
Membrane primary amine oxidase
Molecular Weight
84621.27 Da
References
  1. Tipnis UR, Tao M, Boor PJ: Purification and characterization of semicarbazide-sensitive amine oxidase from porcine aorta. Cell Mol Biol (Noisy-le-grand). 1992 Aug-Sep;38(5-6):575-84. [PubMed:1483111]
  2. Kumar D, Trent MB, Boor PJ: Allylamine and beta-aminopropionitrile induced aortic medial necrosis: mechanisms of synergism. Toxicology. 1998 Feb 6;125(2-3):107-15. [PubMed:9570326]
  3. Chiche F, Le Guillou M, Chetrite G, Lasnier F, Dugail I, Carpene C, Moldes M, Feve B: Antidepressant phenelzine alters differentiation of cultured human and mouse preadipocytes. Mol Pharmacol. 2009 May;75(5):1052-61. doi: 10.1124/mol.108.052563. Epub 2009 Feb 6. [PubMed:19201819]
  4. Biasi D, Caramaschi P, Pacor ML, Carletto A, Melchiori S, Manzo T, Bambara LM: [Multiple osseous avascular necrosis in a patient with systemic lupus erythematosus with antiphospholipid antibody positivity]. Recenti Prog Med. 1995 Nov;86(11):449-50. [PubMed:8539478]
  5. MacKenzie EM, Grant SL, Baker GB, Wood PL: Phenelzine causes an increase in brain ornithine that is prevented by prior monoamine oxidase inhibition. Neurochem Res. 2008 Mar;33(3):430-6. Epub 2007 Aug 31. [PubMed:17768678]
  6. Lizcano JM, Fernandez de Arriba A, Tipton KF, Unzeta M: Inhibition of bovine lung semicarbazide-sensitive amine oxidase (SSAO) by some hydrazine derivatives. Biochem Pharmacol. 1996 Jul 26;52(2):187-95. [PubMed:8694842]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Succinate-semialdehyde dehydrogenase binding
Specific Function
Catalyzes the conversion of gamma-aminobutyrate and L-beta-aminoisobutyrate to succinate semialdehyde and methylmalonate semialdehyde, respectively. Can also convert delta-aminovalerate and beta-al...
Gene Name
ABAT
Uniprot ID
P80404
Uniprot Name
4-aminobutyrate aminotransferase, mitochondrial
Molecular Weight
56438.405 Da
References
  1. MacKenzie EM, Grant SL, Baker GB, Wood PL: Phenelzine causes an increase in brain ornithine that is prevented by prior monoamine oxidase inhibition. Neurochem Res. 2008 Mar;33(3):430-6. Epub 2007 Aug 31. [PubMed:17768678]
  2. Tanay VA, Parent MB, Wong JT, Paslawski T, Martin IL, Baker GB: Effects of the antidepressant/antipanic drug phenelzine on alanine and alanine transaminase in rat brain. Cell Mol Neurobiol. 2001 Aug;21(4):325-39. [PubMed:11775064]
  3. McKenna KF, McManus DJ, Baker GB, Coutts RT: Chronic administration of the antidepressant phenelzine and its N-acetyl analogue: effects on GABAergic function. J Neural Transm Suppl. 1994;41:115-22. [PubMed:7931216]
  4. McManus DJ, Baker GB, Martin IL, Greenshaw AJ, McKenna KF: Effects of the antidepressant/antipanic drug phenelzine on GABA concentrations and GABA-transaminase activity in rat brain. Biochem Pharmacol. 1992 Jun 9;43(11):2486-9. [PubMed:1610412]
  5. Todd KG, Baker GB: GABA-elevating effects of the antidepressant/antipanic drug phenelzine in brain: effects of pretreatment with tranylcypromine, (-)-deprenyl and clorgyline. J Affect Disord. 1995 Dec 13;35(3):125-9. [PubMed:8749840]
  6. Todd KG, Baker GB: Neurochemical effects of the monoamine oxidase inhibitor phenelzine on brain GABA and alanine: A comparison with vigabatrin. J Pharm Pharm Sci. 2008 May 16;11(2):14s-21s. [PubMed:19203467]
  7. McKenna KF, Baker GB, Coutts RT: N2-acetylphenelzine: effects on rat brain GABA, alanine and biogenic amines. Naunyn Schmiedebergs Arch Pharmacol. 1991 May;343(5):478-82. [PubMed:1881457]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Pyridoxal phosphate binding
Specific Function
Catalyzes the reversible transamination between alanine and 2-oxoglutarate to form pyruvate and glutamate. Participates in cellular nitrogen metabolism and also in liver gluconeogenesis starting wi...
Gene Name
GPT
Uniprot ID
P24298
Uniprot Name
Alanine aminotransferase 1
Molecular Weight
54636.415 Da
References
  1. Todd KG, Baker GB: Neurochemical effects of the monoamine oxidase inhibitor phenelzine on brain GABA and alanine: A comparison with vigabatrin. J Pharm Pharm Sci. 2008 May 16;11(2):14s-21s. [PubMed:19203467]
  2. Tanay VA, Parent MB, Wong JT, Paslawski T, Martin IL, Baker GB: Effects of the antidepressant/antipanic drug phenelzine on alanine and alanine transaminase in rat brain. Cell Mol Neurobiol. 2001 Aug;21(4):325-39. [PubMed:11775064]
  3. McKenna KF, Baker GB, Coutts RT: N2-acetylphenelzine: effects on rat brain GABA, alanine and biogenic amines. Naunyn Schmiedebergs Arch Pharmacol. 1991 May;343(5):478-82. [PubMed:1881457]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Pyridoxal phosphate binding
Specific Function
Catalyzes the reversible transamination between alanine and 2-oxoglutarate to form pyruvate and glutamate.
Gene Name
GPT2
Uniprot ID
Q8TD30
Uniprot Name
Alanine aminotransferase 2
Molecular Weight
57903.11 Da
References
  1. Todd KG, Baker GB: Neurochemical effects of the monoamine oxidase inhibitor phenelzine on brain GABA and alanine: A comparison with vigabatrin. J Pharm Pharm Sci. 2008 May 16;11(2):14s-21s. [PubMed:19203467]
  2. Tanay VA, Parent MB, Wong JT, Paslawski T, Martin IL, Baker GB: Effects of the antidepressant/antipanic drug phenelzine on alanine and alanine transaminase in rat brain. Cell Mol Neurobiol. 2001 Aug;21(4):325-39. [PubMed:11775064]
  3. McKenna KF, Baker GB, Coutts RT: N2-acetylphenelzine: effects on rat brain GABA, alanine and biogenic amines. Naunyn Schmiedebergs Arch Pharmacol. 1991 May;343(5):478-82. [PubMed:1881457]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Pyridoxal phosphate binding
Specific Function
Not Available
Gene Name
GAD65
Uniprot ID
Q9UGI5
Uniprot Name
Glutamic acid decarboxylase
Molecular Weight
47343.69 Da
References
  1. McKenna KF, McManus DJ, Baker GB, Coutts RT: Chronic administration of the antidepressant phenelzine and its N-acetyl analogue: effects on GABAergic function. J Neural Transm Suppl. 1994;41:115-22. [PubMed:7931216]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Serotonin binding
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOA
Uniprot ID
P21397
Uniprot Name
Amine oxidase [flavin-containing] A
Molecular Weight
59681.27 Da
References
  1. MacKenzie EM, Grant SL, Baker GB, Wood PL: Phenelzine causes an increase in brain ornithine that is prevented by prior monoamine oxidase inhibition. Neurochem Res. 2008 Mar;33(3):430-6. Epub 2007 Aug 31. [PubMed:17768678]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Primary amine oxidase activity
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOB
Uniprot ID
P27338
Uniprot Name
Amine oxidase [flavin-containing] B
Molecular Weight
58762.475 Da
References
  1. MacKenzie EM, Grant SL, Baker GB, Wood PL: Phenelzine causes an increase in brain ornithine that is prevented by prior monoamine oxidase inhibition. Neurochem Res. 2008 Mar;33(3):430-6. Epub 2007 Aug 31. [PubMed:17768678]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Runge-Morris M, Feng Y, Zangar RC, Novak RF: Effects of hydrazine, phenelzine, and hydralazine treatment on rat hepatic and renal drug-metabolizing enzyme expression. Drug Metab Dispos. 1996 Jul;24(7):734-7. [PubMed:8818569]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Monooxygenase activity
Specific Function
Exhibits low testosterone 6-beta-hydroxylase activity.
Gene Name
CYP3A43
Uniprot ID
Q9HB55
Uniprot Name
Cytochrome P450 3A43
Molecular Weight
57669.21 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18